ReviewMolecules (Basel, Switzerland)2018
Looking at Marine-Derived Bioactive Molecules as Upcoming Anti-Diabetic Agents: A Special Emphasis on PTP1B Inhibitors.
Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Tropical Seaweeds as a Sustainable Resource Towards Circular Bioeconomy: Insights and Way Forward.Molecular biotechnology · 2026Review
- Marine nutraceuticals and their role in modulating diabetes-induced carcinogenesis.Diabetology & metabolic syndrome · 2026Review
- Marine nutraceuticals as a source of SIRT1 and NRF2 activators for diabetes and aging-related metabolic disorders.Diabetology & metabolic syndrome · 2025Review
- Revolutionizing Diabetes Care: The Role of Marine Bioactive Compounds and Microorganisms.Cell biochemistry and biophysics · 2025Review
- Diabetes Mellitus: Exploring Biomarkers, Complications, and Therapeutic Strategies with a Spotlight on Cyanobacterial Bioactive Compounds - A Comprehensive Review.Current diabetes reviews · 2025Review
- Research impact in randomized controlled trials of diabetes: an altmetric approach.Journal of diabetes and metabolic disorders · 2023Article
- Enzyme Inhibitors from Gorgonians and Soft Corals.Marine drugs · 2023Review
- Hypoglycaemic Molecules for the Management of Diabetes Mellitus from Marine Sources.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Naturally Occurring Organohalogen Compounds-A Comprehensive Review.Progress in the chemistry of organic natural products · 2023Review
- Biological properties and potential of compounds extracted from red seaweeds.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022Review
- Cytotoxicity andHeliyon · 2022Article
- Dual Targeting of PTP1B and Aldose Reductase with Marine Drug Phosphoeleganin: A Promising Strategy for Treatment of Type 2 Diabetes.Marine drugs · 2021Article
- Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update.International journal of molecular sciences · 2021Review
- Molecular Networking Leveraging the Secondary Metabolomes Space ofMarine drugs · 2021Article
- Metabolites of Marine Sediment-Derived Fungi: Actual Trends of Biological Activity Studies.Marine drugs · 2021Review
- Bioactive Properties of Marine Phenolics.Marine drugs · 2020Review
- Phytopharmacological Strategies in the Management of Type 2 DiabetesFoods (Basel, Switzerland) · 2020Review
- Antidiabetic Potential of Marine Brown Algae-a Mini Review.Journal of diabetes research · 2020Review
- Molecular Mechanism of Functional Ingredients in Barley to Combat Human Chronic Diseases.Oxidative medicine and cellular longevity · 2020Review
- Experimental and Computational Study to Reveal the Potential of Non-Polar Constituents fromMarine drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a chronic metabolic disease with high morbimortality rates. DM has two types: type 1, which is often associated with a total destruction of pancreatic beta cells, and non-insulin-dependent or type 2 diabetes mellitus (T2DM), more closely associated with obesity and old age. The main causes of T2DM are insulin resistance and/or inadequate insulin secretion. Protein-tyrosine phosphatase 1B (PTP1B) negatively regulates insulin signaling pathways and plays an important role in T2DM, as its overexpression may induce insulin resistance. Thus, since PTP1B may be a therapeutic target for both T2DM and obesity, the search for novel and promising natural inhibitors has gained much attention. Hence, several marine organisms, including macro and microalgae, sponges, marine invertebrates, sea urchins, seaweeds, soft corals, lichens, and sea grasses, have been recently evaluated as potential drug sources. This review provides an overview of the role of PTP1B in T2DM insulin signaling and treatment, and highlights the recent findings of several compounds and extracts derived from marine organisms and their relevance as upcoming PTP1B inhibitors. In this systematic literature review, more than 60 marine-derived metabolites exhibiting PTP1B inhibitory activity are listed. Their chemical classes, structural features, relative PTP1B inhibitory potency (assessed by IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.